← All themes

Immunotherapy & Oncology

Cancer treatment has moved from poisoning dividing cells towards directing the immune system at the tumour, and towards drugs that carry their payload only to cancerous tissue. It absorbs more drug development spending than any other area.

388 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
1	1 Johnson & Johnson JNJ $612B	2,726	-29	-1%	$233B
2	2 Pfizer PFE $166B	2,324	-53	-2%	$142B
3	3 Merck MRK $364B	2,307	+8	+0.3%	$162B
4	4 AbbVie ABBV $501B	2,003	-17	-0.8%	$80.2B
5	5 Amgen AMGN $230B	1,884	+19	+1%	$89.5B
6	6 Bristol-Myers Squibb BMY $121B	1,815	+38	+2%	$69.7B
7	7 Gilead Sciences GILD $190B	1,464	-20	-1%	$64.5B
8	8 Novartis NVS $279B	1,091	-3	-0.3%	$21.2B
9	9 GSK GSK $95.9B	806	+2	+0.2%	$12.1B
10	10 Regeneron Pharmaceuticals REGN $80.1B	633	-25	-4%	$20.4B
11	11 AstraZeneca AZN $251B	556	+9	+2%	$20.5B
12	12 Incyte INCY $22.6B	497	-14	-3%	$14.7B
13	13 DELISTED Exact Sciences EXAS	475	+3	+0.6%	$10.3B
14	14 Jazz Pharmaceuticals JAZZ $13.6B	406	-10	-2%	$6.55B
15	15 Exelixis EXEL $15.1B	340	-6	-2%	$4.2B
16	SGEN 16 DELISTED Seagen Inc. Common Stock SGEN	326	+2	+0.6%	$14.1B
17	17 Takeda Pharmaceutical TAK $60.7B	317	-30	-9%	$2.45B
18	18 NeoGenomics NEO $2.17B	253	0	0%	$1.67B
19	19 Qiagen QGEN $9.41B	244	-18	-7%	$4.74B
20	20 Guardant Health GH $21.9B	242	+25	+12%	$4.72B
21	21 Myriad Genetics MYGN $397M	221	-14	-6%	$2.23B
22	22 DELISTED Blueprint Medicines BPMC	220	0	0%	$3.78B
23	23 Halozyme HALO $13.3B	210	+8	+4%	$1.96B
24	24 Kyntra Bio KYNB $22.5M	210	+20	+11%	$2.25B
25	25 BeOne Medicines Ltd ONC $39.8B	196	-7	-3%	$6.12B